ライフサイエンスコーパス: dyspepsia

1 sis, evaluation, and treatment of functional dyspepsia.

2 ne gastritis, gastric cancer, and functional dyspepsia.

3 e gastric accommodation, to treat functional dyspepsia.

4 ex- and age-matched patients with functional dyspepsia.

5 gastrointestinal malignancy in patients with dyspepsia.

6 f gastric syphilis in a patient with chronic dyspepsia.

7 responsible for sensations of satiety and of dyspepsia.

8 models, controlling for comorbid functional dyspepsia.

9 gets for ameliorating symptoms of functional dyspepsia.

10 ia and had no other diagnosis to account for dyspepsia.

11 s commonly performed to evaluate symptoms of dyspepsia.

12 randial symptoms in patients with functional dyspepsia.

13 l sensation contribute to the development of dyspepsia.

14 ere not associated with an increased risk of dyspepsia.

15 association with the very common symptom of dyspepsia.

16 nts in irritable bowel syndrome and diabetic dyspepsia.

17 Maybe it was the Hippocratic description of dyspepsia.

18 radication therapy in patients with nonulcer dyspepsia.

19 herapy; and 5) assessed symptoms of nonulcer dyspepsia.

20 or H. pylori produced only a 5% reduction in dyspepsia.

21 amous epithelium of patients with functional dyspepsia.

22 s about H. pylori-seropositive patients with dyspepsia.

23 e (IBS) and 23 (28.8%) had one of functional dyspepsia.

24 this gastritis predisposes to NSAID-related dyspepsia.

25 itial management strategy for uninvestigated dyspepsia.

26 om patients with gastritis alone or nonulcer dyspepsia.

27 l therapy in the management of patients with dyspepsia.

28 ntagonists are used to prevent recurrence of dyspepsia.

29 e management of patients with a new onset of dyspepsia.

30 has been proposed for initial management of dyspepsia.

31 implicated in the pathogenesis of functional dyspepsia.

32 7%) met the Rome III criteria for functional dyspepsia.

33 smoking status were associated with organic dyspepsia.

34 ny of the diagnostic criteria for functional dyspepsia.

35 ic ulcer and 56 were diagnosed as functional dyspepsia.

36 omach distention in patients with functional dyspepsia.

37 related symptoms in patients with functional dyspepsia.

38 commodation, is also effective in functional dyspepsia.

39 n, diarrhea, vomiting, food intolerance, and dyspepsia.

40 ssant therapy may be effective in functional dyspepsia.

41 an endoscopy, but most will have functional dyspepsia.

42 other area for future research in functional dyspepsia.

43 ii and H. felis was low in our patients with dyspepsia.

44 ts with scores >/= 6 were considered to have dyspepsia.

45 astrointestinal reflux disease or functional dyspepsia.

46 astric pathology in patients presenting with dyspepsia.

47 8.3% and 11.4%, respectively) and functional dyspepsia (1.9% and 3.3%, respectively).

48 BS [4.4%], 2 of 201 patients with functional dyspepsia [1%], and 1 of 311 patients with functional ab

49 ollows: irritable bowel syndrome (IBS), 3.0; dyspepsia, 1.8; constipation, 3.9; gastroesophageal refl

50 .1%), painful conditions (15.4% vs 8.4%) and dyspepsia (10.9% vs 5.2%).

51 itable bowel syndrome = 91(4.9%), functional dyspepsia = 11 (0.6%), abdominal migraine = 37 (1.9%) an

52 number of patients reporting nausea-vomiting-dyspepsia (20.6% vs. 8%, P=0.007), diarrhea (34.3% vs. 2

53 heral neuropathy (25 [31%] vs 14 [19%]), and dyspepsia (21 [26%] vs 9 [12%]); most were of mild-to-mo

54 de group), diarrhoea (36 [12%] vs 36 [12%]), dyspepsia (24 [8%] vs 18 [6%]), and vomiting (21 [7%] vs

55 onstipation (4%, 9%), anorexia (3%, 7%), and dyspepsia (3%, 7%).

56 ed GERD/heartburn (38.1%) and abdominal pain/dyspepsia (31.0%).

57 ausea (125 [36%] of 345 vs 60 [17%] of 347), dyspepsia (66 [19%] vs 26 [7%]), vomiting (47 [14%] vs 1

58 delpar 50 mg, and one on seladelpar 200 mg), dyspepsia (8%; two patients on seladelpar 50 mg and one

59 were headache (11% sildenafil, 2% placebo), dyspepsia (9% sildenafil, 0% placebo), and respiratory t

60 Dyspepsia, a ubiquitous condition in the United States,

61 Outpatients with uninvestigated dyspepsia, according to Rome III criteria, answered a dy

62 Dyspepsia affects up to 40% of the general population an

63 did not differ between groups for ulcers or dyspepsia alone, per-protocol analysis, or final H. pylo

64 he vagal nerve block group were heartburn or dyspepsia and abdominal pain attributed to therapy; all

65 ferred to gastroenterology for evaluation of dyspepsia and dysphagia.

66 haracteristic of diseases such as functional dyspepsia and gastroesophageal reflux disease (e.g. vomi

67 care billing claims to identify diagnoses of dyspepsia and GERD among Medicare beneficiaries transpla

68 d studies 1) examined patients with nonulcer dyspepsia and H. pylori infection; 2) used combination t

69 16 men) met Rome II criteria for functional dyspepsia and had no other diagnosis to account for dysp

70 rly in subgroups of patients with functional dyspepsia and IBS.

71 racterize patients who receive endoscopy for dyspepsia and measure predictors of primary endoscopic o

72 Patients with reflux dyspepsia and nonreflux dyspepsia were identified from J

73 placed on regional gastric motor function in dyspepsia and on the role of fundic relaxation and accom

74 into the pathogenesis of chronic functional dyspepsia and provide a potential model for further stud

75 110 individuals comprising 463 controls with dyspepsia and reflux symptoms and 647 BE cases swallowed

76 f gastroesophageal reflux disease (GERD) and dyspepsia and their associations with graft survival and

77 esophageal reflux disease (GERD), functional dyspepsia and, possibly, pancreatitis.

78 EGD was most commonly performed to evaluate dyspepsia and/or abdominal pain (23.7%), dysphagia (20%)

79 fied as having IBS, 201 as having functional dyspepsia, and 311 as having functional abdominal pain,

80 e chronic fatigue syndrome, skin conditions, dyspepsia, and a clinically insignificant decrease in th

81 ere acneiform rash, diarrhea, hand reaction, dyspepsia, and anemia.

82 s irritable bowel syndrome (IBS), functional dyspepsia, and functional chest pain.

83 hose of eosinophilic esophagitis, functional dyspepsia, and gastroparesis, posing a challenge for pat

84 c covariates, the incidence of constipation, dyspepsia, and GERD was approximately 1.5-old higher (P

85 antly associated with chest pain, dysphagia, dyspepsia, and globus sensation.

86 -liver disease, irritable bowel syndrome and dyspepsia, and inflammatory bowel disease.

87 rpus biopsies from 60 patients with nonulcer dyspepsia, and results were correlated with the presence

88 Patients had chronic diarrhea, vomiting, dyspepsia, and weight loss for 1 month to 3 years.

89 odestly in identifying those with functional dyspepsia, and were not significantly superior to previo

90 zema/psoriasis (aOR 3.30, 95% CI 3.14-3.48), dyspepsia (aOR 2.20, 95% CI 2.15-2.25) and chronic sinus

91 However, symptoms of functional dyspepsia are often worse after a meal, so studies of po

92 wing recognition of nonulcer (or functional) dyspepsia as an entity that affects a sizable subset of

93 ought to determine estimates of the risks of dyspepsia associated with NSAIDs.

94 ation contribute to postprandial symptoms in dyspepsia, but the controlling mechanisms are unclear.

95 ofenamate, or piroxicam increase the risk of dyspepsia by about 3-fold.

96 Dyspepsia can be managed by initial endoscopy and treatm

97 und pathogen-specific increased risk of IBS, dyspepsia, constipation and GERD.

98 It appears that the risk of dyspepsia, constipation, and GERD are higher among those

99 d side effects were reported in 38%; nausea, dyspepsia, constipation, and sedation were the most comm

100 Ulcer-free patients with mild dyspepsia continued NSAIDs but not antiulcer treatment.

101 %; odds ratio, 1.38 [CI, 1.06 to 1.80]), and dyspepsia (deployed, 9.1%; nondeployed, 6.0%; odds ratio

102 Eradication of H. pylori in patients with dyspepsia despite more negative trials is likely to cont

103 adication in infected patients with nonulcer dyspepsia, despite a number of negative efficacy studies

104 stemic symptoms (eg, flushing, palpitations, dyspepsia, diarrhea, bone pain) that can be severe and p

105 wn not to be associated with ulcer (nonulcer dyspepsia) do not now provide an indication for testing.

106 Although functional dyspepsia does not impart any increased risks to long-te

107 Among pediatric patients with dyspepsia evaluated by endoscopy and biopsy, those with

108 llion per year, and patients with functional dyspepsia experience a markedly reduced quality of life.

109 as to determine the prevalence of functional dyspepsia (FD) among patients with hepatitis C.

110 ; irritable bowel syndrome (IBS), functional dyspepsia (FD) and chronic fatigue (CF).

111 esophageal reflux disease (GERD), functional dyspepsia (FD) and irritable bowel syndrome (IBS) are co

112 Symptoms suggestive of functional dyspepsia (FD) and irritable bowel syndrome (IBS) freque

113 Functional dyspepsia (FD) is a functional gastrointestinal disorder

114 Functional dyspepsia (FD) is a gastrointestinal disorder characteri

115 Functional dyspepsia (FD) is associated with anxiety but it is not

116 It has been reported that functional dyspepsia (FD) is associated with homozygous genotypes o

117 re frequently prescribed to treat functional dyspepsia (FD), a common disorder characterized by upper

118 abnormalities have been noted in functional dyspepsia (FD), their pathogenesis is poorly understood.

119 estinal and systemic symptoms, in functional dyspepsia (FD).

120 rritable bowel syndrome (IBS) and functional dyspepsia (FD).

121 epigastric pain in patients with functional dyspepsia (FD); the etiology and cellular mechanisms of

122 epigastric pain in patients with functional dyspepsia (FD); the etiology and cellular mechanisms of

123 Organic dyspepsia findings were analyzed with different variable

124 charges in the first year after the onset of dyspepsia for patients managed by initial endoscopy or e

125 a-regression identified an increased risk of dyspepsia for users of specific NSAIDs (adjusted odds ra

126 The consumption of medicines for dyspepsia (from 3.7 to 2.4 pills/month) and painkillers

127 Rome III criteria as having IBS, functional dyspepsia, functional abdominal pain, or abdominal migra

128 fore conclude that in patients with nonulcer dyspepsia, H. pylori carriage is associated with increas

129 CD patients with dyspepsia had significantly (p<0.05) prolonged gastric e

130 The endoscopic diagnosis of uninvestigated dyspepsia in our setting showed a predominance of functi

131 this infection might lower the prevalence of dyspepsia in the community and improve quality of life.

132 Five (8%) of 60 participants had dyspepsia in the placebo group.

133 Symptoms of functional dyspepsia, including epigastric pain, early satiety, and

134 ges 8-16 years, who underwent evaluation for dyspepsia, including upper endoscopy.

135 Validated Nepean dyspepsia index-short form (NDI-SF) was used to assess t

136 iarrhea, irritable bowel syndrome, non-ulcer dyspepsia, infant dyschezia, and functional constipation

137 Patients with peptic ulcer or functional dyspepsia infected by H. pylori were randomized to treat

138 While NSAIDs also cause dyspepsia, inhibition of prostaglandin synthesis may red

139 In H. pylori-seropositive patients with dyspepsia, initial anti-H. pylori therapy is the most co

140 Dyspepsia is a frequent syndrome in our country, where t

141 Functional dyspepsia is a heterogeneous disorder involving a number

142 Functional dyspepsia is a highly prevalent disorder that accounts f

143 is now largely accepted that noninvestigated dyspepsia is an indication for testing for and treating

144 c imaging modalities, the pathophysiology of dyspepsia is becoming better understood and recognized a

145 ere are also data to suggest that functional dyspepsia is caused by subtle manifestations of inflamma

146 burden of evaluating and treating functional dyspepsia is estimated to be at least $1 billion per yea

147 The initial management of dyspepsia is well established, but managing those with c

148 stention, an important feature of functional dyspepsia, is assessed by stepwise balloon distention of

149 past or current peptic ulcer or troublesome dyspepsia led to impaired healing of gastric ulcers and

150 uld otherwise prevail and mask ulcer-related dyspepsia, making anticipatory management difficult.

151 Their use in dyspepsia management strategies needs further refinement

152 The pathophysiology of functional dyspepsia may involve abnormal processing of visceral st

153 Dyspepsia may result from gastroparesis and antral diste

154 expectations, psychological stress, hunger, dyspepsia, micronutrient deficiencies (Fe, Zn, and Ca),

155 esentation included epigastric pain (n = 6), dyspepsia (n = 4), and nausea and vomiting (n = 4).

156 as well tolerated, but mild GI side-effects (dyspepsia, nausea and abdominal pain) were described in

157 cific gastrointestinal complaints, including dyspepsia, nausea, vomiting, and diarrhea.

158 n inactive duodenal ulcer (iDU) or non-ulcer dyspepsia (NUD).

159 In nonulcer dyspepsia, numerous RCTs have yielded conflicting result

160 y specimens were obtained from patients with dyspepsia on esophagogastroduodenoscopy (EGD) for rapid

161 lated problems such as functional heartburn, dyspepsia or even eosinophilic oesophagitis.

162 mbers, or incidentally at endoscopy done for dyspepsia or reflux.

163 Dyspepsia or symptoms of gastro-oesophageal reflux were

164 -6.0), dysphagia (OR, 4.7; 95% CI, 2.9-7.4), dyspepsia (OR, 3.1; 95% CI, 1.9-5.0), and globus sensati

165 disorder such as irritable bowel, functional dyspepsia, or abdominal migraine.

166 with current or previous peptic ulceration, dyspepsia, or both who continued to use NSAIDs.

167 did not affect the rate of peptic ulcers or dyspepsia over 6 months.

168 pared with usual management in patients with dyspepsia over age 50 years presenting to their primary

169 diagnosed most often with IBS (p = 0.13) or dyspepsia (p = .036).

170 thy controls and 62 patients with functional dyspepsia participated in a gastric barostat study at Le

171 and sex-matched duodenal ulcer and nonulcer dyspepsia patients (16 each).

172 hundred and sixty-four (164) uninvestigated dyspepsia patients were enrolled.

173 de, reduces dyspepsia symptoms in functional dyspepsia patients.

174 c fatigue syndrome, dermatologic conditions, dyspepsia, physical health-related quality of life (Shor

175 on in the United States include treatment of dyspepsia, physician education on disease associations w

176 A total of 86% met criteria for functional dyspepsia, primarily postprandial distress syndrome.

177 er interviewed participants with a validated dyspepsia questionnaire and the psychological general we

178 , according to Rome III criteria, answered a dyspepsia questionnaire and underwent esophagogastroduod

179 eatment group had dyspepsia; the severity of dyspepsia ranged from mild to severe, with four (21%) of

180 ro and microscopic bile reflux and impact on dyspepsia related quality of life in long-term survivors

181 (NDI-SF) was used to assess the severity of dyspepsia-related quality of life and compared with age

182 Treatment of functional dyspepsia remains a challenge.

183 relationship between H. pylori gastritis and dyspepsia remains controversial, there is no evidence fr

184 status; diagnosis (ulcer disease or nonulcer dyspepsia); resistance to clarithromycin, imidazoles, or

185 x disease (GERD) (RR, 1.9; 95% CI, 1.4-2.6), dyspepsia (RR, 3.3; 95%, 1.4-7.7), and constipation (RR,

186 In adults with functional dyspepsia seen in a tertiary referral practice, decrease

187 th the hypothesis that in such a population, dyspepsia should have been relatively less common.

188 ian patients with peptic ulcer or functional dyspepsia showed no significant difference in efficacy o

189 Primary outcomes were effect of treatment on dyspepsia symptoms and cost effectiveness.

190 s that a new prokinetic, acotiamide, reduces dyspepsia symptoms in functional dyspepsia patients.

191 n implicated in the generation of functional dyspepsia symptoms.

192 lar between the treatment groups, except for dyspepsia (ten [7%] in the ozanezumab group vs four [3%]

193 hat used a specifically stated definition of dyspepsia (that is, upper abdominal pain or discomfort),

194 In patients with nonulcer dyspepsia, the financial benefits of initial anti-H. pyl

195 enefit of anti-H. pylori therapy in nonucler dyspepsia, the strategy outlined in this analysis can be

196 st frequent adverse events were headache and dyspepsia; the majority of adverse events were mild or m

197 %) of 60 patients in the treatment group had dyspepsia; the severity of dyspepsia ranged from mild to

198 It is important to know the causes of dyspepsia to establish the therapeutic approach.

199 constipation (two [<1%] vs three [<1%]), and dyspepsia (two [<1%] vs three [<1%]).

200 nt in women than men, functional chest pain, dyspepsia, vomiting, and anorectal pain do not appear to

201 ageal or gastric malignancy in patients with dyspepsia was associated with increasing age, male sex,

202 Organic dyspepsia was associated with infection, age and smoking

203 ed to define the presence of true functional dyspepsia was epigastric pain, early satiety or postpran

204 Functional dyspepsia was found in 66% of the patients (20% with nor

205 Dyspepsia was not reported as an outcome in the case con

206 most commonly abdominal pain, diarrhoea, and dyspepsia, was nearly three times higher in the diclofen

207 A medical history, including a history of dyspepsia, was taken by a physician and immunoglobulin G

208 -year cumulative incidences of GERD, RE, and dyspepsia were 20%, 5%, and 6%, respectively.

209 lthough the Rome III criteria for functional dyspepsia were defined 7 years ago, they have yet to be

210 Two hundred-fifty patients with dyspepsia were enrolled in the study.

211 Patients with reflux dyspepsia and nonreflux dyspepsia were identified from January 2000 to June 2002

212 me, functional abdominal pain, or functional dyspepsia were randomized to 4 weeks of placebo or amitr

213 Headache, flushing, and dyspepsia were reported frequently during treatment, but

214 Headache, flushing, and dyspepsia were the most common adverse effects in the do

215 GI bleeding and dyspepsia were the most common symptoms.

216 linicians in the management of patients with dyspepsia who are seropositive for H. pylori are lacking

217 criteria identified patients with functional dyspepsia with 60.7% sensitivity, 68.7% specificity, a p

218 criteria identified patients with functional dyspepsia with 71.4% sensitivity, 55.6% specificity, a p

219 ratio (OR) for treatment success in nonulcer dyspepsia with H. pylori eradication therapy compared wi

220 rges than initial endoscopy if patients with dyspepsia with H. pylori receive antimicrobial therapy w

221 Dyspepsia, with and without reflux symptoms, accounted f